Edition:
United States

Ucb SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

59.43EUR
22 Sep 2017
Change (% chg)

-- (--)
Prev Close
€59.43
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
392,369
52-wk High
€79.05
52-wk Low
€54.84

Select another date:

Thu, Sep 21 2017

BRIEF-UCB anti-epileptic drug Vimpat (Lacosamide) receives EU approval for paediatric use

* ANTI-EPILEPTIC DRUG VIMPAT (LACOSAMIDE) RECEIVES EU APPROVAL FOR PAEDIATRIC USE

BRIEF-UCB's Briviact approved by FDA as monotherapy treatment of partial-onset seizures in adults

* NEW INDICATION FOR BRIVIACT (BRIVARACETAM): UCB'S NEWEST ANTIEPILEPTIC DRUG APPROVED BY FDA AS MONOTHERAPY TREATMENT OF PARTIAL-ONSET SEIZURES IN ADULTS Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

BRIEF-UCB and Amgen announce detailed results from the phase 3 ARCH study

* ANNOUNCED ON MONDAY, TOGETHER WITH AMGEN , DETAILED RESULTS FROM THE PHASE 3 ARCH STUDY

BRIEF-UCB H1 net sales up at EUR 2.04 billion; increases FY 2017 outlook

* H1 NET SALES EUR 2.04 BILLION VERSUS EUR 1.85 BILLION YEAR AGO

UCB increases 2017 outlook as profit rises in first half

BRUSSELS, July 27 Belgian pharmaceutical company UCB on Thursday increased its 2017 revenue and profit outlook, after beating analysts' forecasts in the first half of the year.

BRIEF-UCB and Dermira announce US and EU regulatory submissions for Cimzia

* UCB AND DERMIRA ANNOUNCE U.S. AND EU REGULATORY SUBMISSIONS FOR CIMZIA (CERTOLIZUMAB PEGOL) FOR THE TREATMENT OF MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS Source text: http://bit.ly/2ty2bhV Further company coverage: (Gdynia Newsroom)

BRIEF-UCB anti-epileptic drug Vimpat receives EU CHMP positive opinion

* ANTI-EPILEPTIC DRUG VIMPAT RECEIVES EU CHMP POSITIVE OPINION FOR BOTH MONOTHERAPY AND ADJUNCTIVE THERAPY IN CHILDREN AGED 4 YEARS AND OLDER WITH EPILEPSY

BRIEF-UCB's Bimekizumab demonstrates skin clearance in psoriasis study

* READY TO ADVANCE PHASE 3 CLINICAL DEVELOPMENT PROGRAM FOR BIMEKIZUMAB IN PSORIASIS

Heart safety clouds hopes for Amgen, UCB bone drug approval

Amgen Inc and UCB SA no longer expect their experimental osteoporosis drug to win U.S. approval this year after a higher rate of serious heart-related side effects were observed in a late-stage clinical trial.

UPDATE 4-Heart safety clouds hopes for Amgen, UCB bone drug approval

* UCB shares drop 18 pct, Amgen shares down 2 pct (Adds Amgen, UCB, Radius Health share moves)

Select another date: